Microtubule effects of welwistatin, a cyanobacterial indolinone that circumvents multiple drug resistance

Molecular Pharmacology

Volumn 49, Issue 2, 1996, Pages 288-294

  Zhang, Xinqun ^a   Smith, Charles D ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; UNCLASSIFIED DRUG; WELWISTATIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLUE GREEN ALGA; DRUG EFFECT; DRUG ISOLATION; HUMAN; HUMAN CELL; MICROTUBULE; MULTIDRUG RESISTANCE; OVARY CARCINOMA; PRIORITY JOURNAL;

ALKALOIDS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CELL CYCLE; CELL DIVISION; CELL LINE; CELL SURVIVAL; COLCHICINE; CYANOBACTERIA; CYTOSKELETON; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DNA, NEOPLASM; DRUG RESISTANCE, MULTIPLE; ETOPOSIDE; FEMALE; GTP PHOSPHOHYDROLASES; HUMANS; KINETICS; MICROTUBULES; MUSCLE, SMOOTH, VASCULAR; OVARIAN NEOPLASMS; TUBULIN;

EID: 0030026104     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Mandelkow, E., and E M. Mandelkow. Microtubule structure. Curr. Opin. Struct. Biol. 4:171-179 (1994).
2. Gerzon, K. Dimeric Catharanthns alkloids, in Anticancer Agents Based on Natural Product Models (J. M. Cassady and J. D. Douros, eds.). Academic Press, New York, 271-331 (1980)
3. Taylor, E. W. The mechanism of colchicine inhibition of mitosis. J. Cell. Biol. 25:145-160 (1965).
4. Schiff, P. B., and S. B. Horwitz. Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl. Acad. Sci. USA 77:1561-1565 (1980).
5. Toso, R. J., M. A. Jordan, K. W. Farrell, B. Matsumoto, and L. Wilson. Kinetic stabilization of microtubule dynamic instability in vitro by vinblastine. Biochemistry 32:1285-1293 (1993).
6. M. A. Jordan, R. J. Toso, D. Thrower, and L. Wilson. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc. Natl. Acad. Sci. USA 90:5552-9556 (1993).
7. Rowinsky, E. K., and R. C. Donehower. The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmacol. Ther. 52:35-84 (1991).
8. Deconti, R. C., and W. A. Creasey. Clinical aspects of the dimeric Catharanthus alkaloids, in The Catharanthus Alkaloids: Botany, Chemistry, Pharmacology and Clinical Use (W. I. Taylor and N. R. Farnsworth, eds.). Marcel Dekker, New York, 237-278 (1975).
9. Runowicz, C D., P. H. Wiernik, A. I. Einzig, G. L. Goldberg, and S. B. Horwitz. Taxol in ovarian cancer. Cancer (Phila.) 71:1591-1596 (1993).
10. Calabresi, P., J. Clark, A. R. Hanauske, and M. C. Wiemann. Pharmacology of antineoplastic agents, in Medical Oncology (P. Calabresi and P. S. Schein, eds.). 2nd ed. McGraw-Hill, New York, 263-321 (1993).
11. Endicott, J A., and V. Ling The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem. 58:137-171(1989).
12. Gottesman, M. M., and I. Pastan. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62:385-427 (1993).
13. Moscow, J A., and K. H. Cowan. Multidrug resistance. J. Natl. Cancer Inst 80:14-20 (1988).
14. Ford, J. M., and W. N. Hait Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev. 42:155-199 (1990).
15. Raderer, M , and W. Scheithauer. Clinical trials of agents that reverse multidrug resistance: a literature review. Cancer (Phila.) 72:3553-3563 (1993).
16. Speicher, L. A., L. R. Barone, A. E. Chapman, G. R. Hudes, N Laing, C. D. Smith, and K. D. Tew. P-glycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine. J. Natl. Cancer Inst. 86: 688-694 (1994).
17. Hudes, G. R., R. Greenberg, R. L. Krigel, S. Fox. R Scher, S. Litwin, P. Watts, L. Speicher, K. D. Tew, and R. Comis. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J. Clin. Oncol. 10:1754-1761 (1992).
18. Seidman, A., H. I. Scher, D. Petrylak, D. D. Dershaw, and T. Curley. Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone-refractory prostate cancer. J. Urol. 147:931-934 (1992).
19. Hudes, G. R., C. Obasaju, A. Chapman, J. Gallo, C. McAleer, and R. Greenberg. Phase I study of paclitaxel and estramustine: preliminary activity in hormone-refractory prostate cancer. Semin. Oncol. 22: 6-11 (1995).
20. Smith, C D, X. Zhang, S. L. Mooberry, G. M. L. Patterson, and R. E. Moore. Cryptophycin: a new antimicrotubule agent active against drug-resistant cells. Cancer Res. 54:3779-3784 (1994).
21. Stratmann, K., R. E. Moore, R. Bonjouklian, J. B. Deeter, G. M. L. Patterson, S. Shaffer, C. D Smith, and T. A. Smitka. Welwitindolinones, unusual alkaloids from the blue-green algae Hapalosiphon welwitschii and Westiella intricata: relationship to fischerindoles and hapalindoles. J. Am. Chem. Soc. 116:9935-9942 (1994).
22. Smith, C. D., J. T. Zilfou, K. Stratmann, G M. L. Patterson, and R. E. Moore. Welwitindolinone analogues that reverse P-glycoprotein-mediated multiple drug resistance. Mol. Pharmacol. 47:241-247 (1995).
23. Skehan, P., R. Stoneng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J T. Warren, H. Bokesch, S. Kenney, and M. R. Boyd. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82:1107-1112 (1990).
24. Tiwari, S. C., and K. A. Suprenant A pH- and temperature-dependent cycling method that doubles the yield of microtubule protein. Analyt. Biochem. 251:96-103 (1993).
25. Vallee, R. B. Purification of brain microtubules and microtubule-associated protein 1 using taxol. Methods Enzymol 134:89-104 (1986).
26. Borisy, G. G. A rapid method for quantitative determination of microtubule protein using DEAE-cellulose filters. Analyt. Biochem. 13:373-385 (1972).
27. Heusele, C , and M -F. Carlier. GTPase activity of the tubulin-colchicine in relation with tubulin-tubulin interactions Biochem. Biophys. Res. Commun. 103:332-338 (1981).
28. Smith, C. D., and W W. Wells. Solubilization and reconstitution of a nuclear envelope associated ATPase. synergistic activation by RNA and polyphosphoinositides. J Biol. Chem 259:11890-11894 (1984).
29. van der Graaf, W. T. A., E. G. E. de Vries, H. Timmer-Bosscha, G. J. Meersma, G. Mesander, E. Vellenga, and N. H. Mulder. Effects of amiodarone, cyclosporin A, and PSC 833 on the cytotoxicity of mitoxanthrone, doxorubicin, and vincristine in non-P-glycoprotein human small cell lung cancer cell lines. Cancer Res. 54:5368-5373 (1994).
30. Manfredi, J J., and S. B. Horwitz. Taxol: an antimitotic agent with a new mechanism of action. Pharmacol. Ther. 25:83-125 (1984).
31. Smith, C. D , S L. Mooberry, X. Zhang, and A. M. Helt. A sensitive assay for taxol and other microtubule-stabilizing agents. Cancer Lett 79:213-219 (1994).
32. Abraham, I., R. L. Dion, C. Duanmu, M. M. Gottesman and E. Hamel. 2 4-Dichlorobenzyl thiocyanate, an antimitotic agent that alters microtubule morphology Proc. Natl. Acad. Sci USA 83:6839-6843 (1986).
33. Pratt, W. B., R. W. Ruddon, W D. Ensminger, and J. Maybaum. Inhibitors of chromatin function, in The Anticancer Drugs. 2nd ed. Oxford University Press, New York, 183-198 (1994).
34. Weisenberg, R. C., G. G. Borisy, and E. W. Taylor. The colchicine-binding protein of mammalian brain and its relation to microtubules. Biochemistry 7:4466-4478 (1968).
35. Hamel, E. Interactions of tubulin with small ligands, in Microtubule Proteins (J. Avila, ed.). CRC Press, Boca Raton, FL, 89-191 (1990).
36. Correia, J. J. Effects of antimitotic agents on tubulin-nucleotide interactions. Pharmacol. Ther. 52:127-147 (1991).
37. Hamel, E., A. V. Blokhin, D. G. Nagle, H.-D. Yoo, and W. H. Gerwick. Limitations in the use of tubulin polymerization assays as a screen for the identification of new antimitotic agents: the potent marine natural product curacin A as an example. Drug Dev. Res. 34:110-120 (1995).
38. Bai, R., C. Duanmu, and E. Hamel. Mechanism of action of the antimitotic drug 2,4-dichlorobenzyl thiocyanate: alkylation of sulfhydryl group(s) of β-tubulin. Biochim. Biophys. Acta 994:12-20 (1989).
39. Na, G. C., and S. N. Timasheff Stoichiometry of the vinblastine-induced self-association of calf brain tubulin. Biochemistry 19:1347-1354 (1980).
40. Andreu, J. M., and S. N. Timasheff. Tubulin bound to colchicine forms polymers different from microtubules. Proc. Natl. Acad. Sci. USA 79:6753-6756 (1982).
41. Sinclair, W. K. Cyclic x-ray responses in mammalian cells in vitro. Radiat Bes. 33:620-643 (1968).